In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio

In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio
Royalty Pharma has bought Massachusetts General Hospital’s (MGH) royalty interest in the inflammatory bowel disease (IBD) therapy Entyvio (vedolizumab) for $94 million. Produced by Millennium Pharmaceuticals, which is part of Takeda, Entyvio is available in more than 60 countries. Sales of the monoclonal antibody exceeded $3 billion last year, a 30% increase over 2018. By acquiring existing royalty interests from original innovators, Royalty Pharma indirectly funds scientific innovation. The company’s portfolio now includes royalty interests in more than 50 approved products. “Because of the discoveries of researchers at Massachusetts General Hospital, Entyvio has improved the lives of hundreds of thousands of patients with IBD,” Pablo Legorreta, founder and CEO of Royalty Pharma, said in a press release. “Through transactions such as this, we are furthering our goal of accelerating innovation and making the life sciences research and development ecosystem more efficient and productive,” Legorreta said. Robert Colvin, an MGH physician and researcher, made the foundational discovery that led to the development of Entyvio, an every-eight-weeks intravenous treatment for adults with moderate-to-severe ulcerative colitis and Crohn’s disease who fail to respond to other therapies. “I find it incredibly exciting that a basic scientific discovery made decades ago in a different field has translated into a treatment that is directly helping so many patients today,” Colvin said. “I feel privileged to have been part of the extraordinary pathology team that moved this work forward.” Approved in 2014 by the U.S. Food and Drug Administration (FDA), the gut-selective maintenance therapy Entyvio works by preventing pro-inflammatory immune cel
Subscribe or to access all post and page content.